Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia.

IF 1.6 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Pharmacogenomics Pub Date : 2026-03-01 Epub Date: 2026-05-15 DOI:10.1080/14622416.2026.2671918
Teodora Karan-Djurasevic, Irena Marjanovic, Natasa Tosic
{"title":"Long non-coding RNAs and survival outcomes in chronic lymphocytic leukemia.","authors":"Teodora Karan-Djurasevic, Irena Marjanovic, Natasa Tosic","doi":"10.1080/14622416.2026.2671918","DOIUrl":null,"url":null,"abstract":"<p><p>Chronic lymphocytic leukemia (CLL) is a highly heterogeneous hematological malignancy characterized by pronounced differences in clinical course and genetic background. While research has historically focused on alterations in protein-coding genes, it is increasingly evident that the non-coding transcriptome plays a pivotal role in CLL pathogenesis and progression. This review explores the emerging field of long non-coding RNAs (lncRNAs) in CLL, and their association with survival outcomes. We discuss how these pleiotropic transcripts act as master regulators of gene expression, orchestrating key cancer-related cellular processes, such as proliferation, apoptosis and communication with the tumor microenvironment. Furthermore, we examine how the aberrant expression of specific lncRNAs correlates with the established clinical and biological prognostic markers, response to treatment and survival of patients. By summarizing current findings, this review evaluates the potential of these regulatory transcripts as prognostic and/or predictive markers, as well as their prospects as innovative therapeutic targets. Understanding the mechanisms of action and functional roles of lncRNAs in pathobiology of CLL cells may contribute to refining risk stratification and developing personalized management strategies for patients with this complex leukemia.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":" ","pages":"159-177"},"PeriodicalIF":1.6000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13203066/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14622416.2026.2671918","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/5/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic lymphocytic leukemia (CLL) is a highly heterogeneous hematological malignancy characterized by pronounced differences in clinical course and genetic background. While research has historically focused on alterations in protein-coding genes, it is increasingly evident that the non-coding transcriptome plays a pivotal role in CLL pathogenesis and progression. This review explores the emerging field of long non-coding RNAs (lncRNAs) in CLL, and their association with survival outcomes. We discuss how these pleiotropic transcripts act as master regulators of gene expression, orchestrating key cancer-related cellular processes, such as proliferation, apoptosis and communication with the tumor microenvironment. Furthermore, we examine how the aberrant expression of specific lncRNAs correlates with the established clinical and biological prognostic markers, response to treatment and survival of patients. By summarizing current findings, this review evaluates the potential of these regulatory transcripts as prognostic and/or predictive markers, as well as their prospects as innovative therapeutic targets. Understanding the mechanisms of action and functional roles of lncRNAs in pathobiology of CLL cells may contribute to refining risk stratification and developing personalized management strategies for patients with this complex leukemia.

长链非编码rna与慢性淋巴细胞白血病的生存结局。
慢性淋巴细胞白血病(CLL)是一种高度异质性的血液系统恶性肿瘤,其特点是在临床病程和遗传背景上存在显著差异。虽然历史上的研究主要集中在蛋白质编码基因的改变上,但越来越明显的是,非编码转录组在CLL的发病和进展中起着关键作用。本文综述了CLL中新兴的长链非编码rna (lncRNAs)及其与生存结果的关系。我们讨论了这些多效转录本如何作为基因表达的主要调控因子,协调关键的癌症相关细胞过程,如增殖、凋亡和与肿瘤微环境的通讯。此外,我们研究了特定lncrna的异常表达如何与既定的临床和生物学预后标志物、对治疗的反应和患者的生存相关。通过总结目前的发现,本综述评估了这些调控转录物作为预后和/或预测标记物的潜力,以及它们作为创新治疗靶点的前景。了解lncrna在CLL细胞病理生物学中的作用机制和功能作用,可能有助于改进这种复杂白血病患者的风险分层和制定个性化的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacogenomics
Pharmacogenomics 医学-药学
CiteScore
3.40
自引率
9.50%
发文量
88
审稿时长
4-8 weeks
期刊介绍: Pharmacogenomics (ISSN 1462-2416) is a peer-reviewed journal presenting reviews and reports by the researchers and decision-makers closely involved in this rapidly developing area. Key objectives are to provide the community with an essential resource for keeping abreast of the latest developments in all areas of this exciting field. Pharmacogenomics is the leading source of commentary and analysis, bringing you the highest quality expert analyses from corporate and academic opinion leaders in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书